Eszopiclone in the Treatment of Insomnia and Fibromyalgia
Primary Purpose
Fibromyalgia, Insomnia
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Eszopiclone
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Fibromyalgia focused on measuring Fibromyalgia, Insomnia, Sleep, Eszopiclone, Lunesta
Eligibility Criteria
Inclusion Criteria:
- Male or female, age 18 through 64.
- Meets ACR criteria for FMS, as determined by rheumatological examination and a medical history review.
- Reports sleep maintenance insomnia (total sleep time of < 6.5 hours or sleep impairment consisting of 3 of 7 nights per week for a month by history) or sleep onset latency insomnia (at least 3 of 7 nights of sleep latency > 30 minutes), as well as clinically significant daytime distress or impairment during the 1 week self assessment prior to baseline.
- Has completed 8th grade and is fluent in English.
- If a female of child bearing potential, the patient must be non-pregnant and either post-menopausal or using an approved birth control method. Acceptable birth control methods include: history of tubal ligation, having a male partner who is sterile, IUDs, birth control pills or other hormonal birth control methods (e.g., birth control patch, Depo-Provera injections), and double-barrier methods (e.g., condom and foam).
- Antidepressant medication will be allowed if the patient has been on a stable dose for at least one month.
Exclusion Criteria:
- Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or endocrine-related arthropathy.
- Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing (central or obstructive apnea), periodic limb movement disorder, or REM sleep behavior disorder.
- Any current, clinically significant medical condition.
- Pregnancy.
- Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain syndrome, or psychoactive substance abuse or dependence.
- Any current psychiatric disorder that would interfere with study participation (investigator judgment).
- Active suicidal ideation.
- Plans to engage in additional psychotherapy during the study.
- Concurrent use of benzodiazepines after 6pm or as a sleep aid.
- Concurrent use of any other sleep aid.
- Concurrent use of analgesics other than acetaminophen or non-steroidal anti-inflammatory medication.
- Concurrent use of any medication that has not been stabilized for at least 1 month prior to screening.
Sites / Locations
- Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Eszopiclone
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change in Total Sleep Time (TST) as Recorded in Patient Diaries
Difference in total sleep time between week 4 and baseline
Secondary Outcome Measures
Wake Time After Sleep Onset (WASO)
Minutes awake after sleep onset as recorded in patient diaries
Sleep Quality
Clinician-rated Overall Severity of Fibromyalgia
Fibromyalgia Impact Questionnaire
Full Information
NCT ID
NCT00392041
First Posted
October 24, 2006
Last Updated
December 8, 2020
Sponsor
Lesley A. Allen, Ph.D.
Collaborators
Sumitomo Pharma America, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00392041
Brief Title
Eszopiclone in the Treatment of Insomnia and Fibromyalgia
Official Title
Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
August 2006 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Lesley A. Allen, Ph.D.
Collaborators
Sumitomo Pharma America, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia. It is hypothesized that participants receiving eszopiclone will report greater improvement in total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than will those receiving placebo.
Detailed Description
Fibromyalgia (FM) is a prevalent, debilitating, and costly syndrome. Although the pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia, but has not been studied in the treatment of FMS. The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia (FMS) in FMS patients. Participants will be randomly selected to receive eszopiclone or placebo. It is hypothesized that participants receiving eszopiclone will report greater improvement in total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than will those receiving placebo.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia, Insomnia
Keywords
Fibromyalgia, Insomnia, Sleep, Eszopiclone, Lunesta
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Eszopiclone
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Eszopiclone
Other Intervention Name(s)
Lunesta
Intervention Description
3mg qpm for 12 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
1 pill qpm for 12 weeks
Primary Outcome Measure Information:
Title
Change in Total Sleep Time (TST) as Recorded in Patient Diaries
Description
Difference in total sleep time between week 4 and baseline
Time Frame
week 4
Secondary Outcome Measure Information:
Title
Wake Time After Sleep Onset (WASO)
Description
Minutes awake after sleep onset as recorded in patient diaries
Time Frame
week 12
Title
Sleep Quality
Time Frame
week 12
Title
Clinician-rated Overall Severity of Fibromyalgia
Time Frame
week 12
Title
Fibromyalgia Impact Questionnaire
Time Frame
week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female, age 18 through 64.
Meets ACR criteria for FMS, as determined by rheumatological examination and a medical history review.
Reports sleep maintenance insomnia (total sleep time of < 6.5 hours or sleep impairment consisting of 3 of 7 nights per week for a month by history) or sleep onset latency insomnia (at least 3 of 7 nights of sleep latency > 30 minutes), as well as clinically significant daytime distress or impairment during the 1 week self assessment prior to baseline.
Has completed 8th grade and is fluent in English.
If a female of child bearing potential, the patient must be non-pregnant and either post-menopausal or using an approved birth control method. Acceptable birth control methods include: history of tubal ligation, having a male partner who is sterile, IUDs, birth control pills or other hormonal birth control methods (e.g., birth control patch, Depo-Provera injections), and double-barrier methods (e.g., condom and foam).
Antidepressant medication will be allowed if the patient has been on a stable dose for at least one month.
Exclusion Criteria:
Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or endocrine-related arthropathy.
Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing (central or obstructive apnea), periodic limb movement disorder, or REM sleep behavior disorder.
Any current, clinically significant medical condition.
Pregnancy.
Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain syndrome, or psychoactive substance abuse or dependence.
Any current psychiatric disorder that would interfere with study participation (investigator judgment).
Active suicidal ideation.
Plans to engage in additional psychotherapy during the study.
Concurrent use of benzodiazepines after 6pm or as a sleep aid.
Concurrent use of any other sleep aid.
Concurrent use of analgesics other than acetaminophen or non-steroidal anti-inflammatory medication.
Concurrent use of any medication that has not been stabilized for at least 1 month prior to screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lesley A. Allen, Ph.D.
Organizational Affiliation
Rutgers, The State University of New Jersey
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School
City
Piscataway
State/Province
New Jersey
ZIP/Postal Code
08854
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Eszopiclone in the Treatment of Insomnia and Fibromyalgia
We'll reach out to this number within 24 hrs